Administration costs of intravenous biologic drugs for rheumatoid arthritis

SpringerPlus

Table 1 Total and administration costs (€2011) of public health care payer by drug regardless of dosing

Drug	Administration (€, N 82) per infusion				Total costs^a(€, N 106) per infusion
	N	*Average*	*S.D.*	*Range*	N	*Average*	*S.D.*	*Range*
Infliximab	52	330.87^b	158.27	25–728	51	3128.21^c	1560.96	647-6648
Rituximab	20	578.38^b	425.65	15–1572	20	2612.37^c	1412.06	342-6147
Abatacept	5	455.60	138.22	334–688	5	1422.80	440.05	1120-2176
Tocilizumab	5	414.63	202.00	263–728	5	1454.00	416.33	1204-2176
Expensive infusion with RA dose	0	NR	NR	NR	5	2873.20	1056.19	1695-3895
Other expensive infusion	0	NR	NR	NR	20	2955.35	2031.26	1390-10213

RA = rheumatoid arthritis. N = number of observations. S.D. = standard deviation. NR = not reported. ^a Includes administration and drug costs. ^b Average IFX administration cost was statistically significantly different from average RTX administration cost (p-value = 0.007). ^c Average IFX total cost was not statistically significantly different from average RTX total cost (p-value = 0.175).